Robert Byrne: Absorb, Synergy, And The Future Of Coronary Stents
Executive Summary
One of the most controversial, and potentially impactful, questions in medical device development today is how to better prevent late events, especially late stent-thrombosis, in coronary stent patients. The two leading answers to this question are a completely bioresorbable drug-eluting stent and a metal drug-eluting stent with a bioresorbable polymer, but there may be even more ideas on the horizon. One of the leading experts in the field and a cardiologist with experience with most of these new technologies, Robert Byrne of Deutsches Herzzentrum in Munich, recently talked to Medtech Insight about the questions that still need to be answered in this field and how it can move forward.
You may also be interested in...
Start-Up Spotlight: Elixir Works To 'Uncage' The Coronary After Intervention
The company is sponsoring INFINITY SWEDEHEART, a randomized trial of its DynamX Bioadaptor, a unique metallic coronary artery implant that adapts to vessel physiology.
EuroPCR 2017: TAVR Continues To Beat Surgery; Bioabsorbable Stents Not Going Away
The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.
OUS Approvals Analysis: Small Companies Dominate International Approvals In April
April was a return to a more typical volume of medical device approvals outside the US after a particularly busy March. And the big names in medtech were mostly quiet in April's OUS approvals, according to Medtech Insight's Approval Tracker.